Skip to main content
Download PDF

Beclin1 and HMGB1 ameliorate the α-synuclein-mediated autophagy inhibition in PC12 cells

Diagnostic Pathology volume 11, Article number: 15 (2016) Cite this article

Abstract

Background

Aberrant α-synuclein aggregation due to the deficiency of ubiquitin-proteasome or of autophagy characterizes the parkinson disease (PD). High mobility group box 1 (HMGB1) is a novel stress sensor to mediate the persistent neuro-inflammation and the consequent progressive neurodegeneration, via controlling the cellular autophagy/apoptosis checkpoint during inflammation. Moreover, HMGB1 has been recently indicated to involve in the autophagic degradation of α-synuclein.

Methods

In the current study, we investigated the influence of the overexpressed α-synuclein of wild type (wt) or mutant type (A53T and A30P, mt) on the cytosolic levels of HMGB1 and Beclin1 and on the starvation-induced autophagy in pheochromocytoma PC12 cells. And then we explored the overexpression of HMGB1 or of Beclin1 on the α-synuclein degradation and on the autophagy in the α-synuclein-overexpressed PC12 cells.

Results

It was demonstrated that α-synuclein overexpression inhibited the trans-location of HMGB1 from nucleus to cytosol and reduced the cytosolic level of Beclin1 in PC12 cells, and inhibited the starvation-induced autophagy via downregulating autophagy-associated markers and via reducing the autophagic vesicles in PC12 cells under starvation. On the other side, the intracellular promotion of either HMGB1 or Beclin1 upregulated the α-synuclein degradation and ameliorated the α-synuclein-mediated autophagy reduction in PC12 cells. However, the exogenous HMGB1 treatment exerted no such regulation in PC12 cells.

Conclusion

In summary, our study confirmed the positive regulation by HMGB1 and Beclin1 on the α-synuclein degradation and on the starvation-induced autophagy in PC12 cells, implying both markers as prominent targets to promote the α-synuclein degradation.

Background

Aberrant α-synuclein aggregation and the followed degeneration of dopaminergic cells [1–4] characterize the parkinson disease (PD). The deficient protein degradation pathways such as ubiquitin-proteasome system (UPS) and autophagy lysosomal pathway (ALP) have been recognized to contribute to the scanty degradation of wild-type (WT) or mutant-type (MT, A53T and A30P) α-synuclein [5, 6]. Moreover, autophagy is the only clearance pathway for the aggregated α-syn [7, 8]. And the both macromolecular complexes, mammalian target of rapamycin (mTOR)-Unc-51 like autophagy activating kinase 1 (ULK1) complex and the Beclin 1-Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) complex [9] are important for α-synuclein degradation [10].

Recently, multiple molecules have been characterized to regulate autophagy via the mTOR-ULK1 or PIK3C3 pathway. Amino acid starvation stimulates phosphorylation of ULK1 by protein phosphatase 2A to form PP2A-B55α complex and induces the ULK1-dependent autophagy [11, 12]. The transcriptional regulation of Annexin A2 also promotes the starvation-induced autophagy, via regulating autophagosome formation by enabling appropriate Autophagy-related protein (ATG) 9A trafficking from endosomes to autophagosomes [13]. Moreover, various markers have been confirmed to regulate autophagy through the PIK3C3 pathway. Dapper1 promotes autophagy by enhancing the Beclin1- vacuolar protein sorting 34 (VPS34)-Atg14L complex formation [14]. Interferon-alpha-2b induces autophagy in hepatocellular carcinoma cells via stimulating Beclin1 pathway [15]. Rho-associated, coiled-coil containing protein kinase 1 (ROCK1) promotes autophagy by binding and phosphorylating Beclin1 at Thr119 under metabolic stress [16]. However, Macrophage stimulating 1 (Mst1) inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2 [17]. And Smad2 binds to the Beclin1 promoter region, transcriptionally regulates autophagy via regulating beclin1 expression [18].

High mobility group box 1 (HMGB1) is a stress sensor that plays a critical role in various physiological and pathological processes including cell development, differentiation, inflammation, metabolism and death [19]. Increasing evidence demonstrates that HMGB1-dependent autophagy promotes chemotherapy resistance [20], sustains tumor metabolism [21], protects against endotoxemia [22] and involves in other pathological processes [23, 24]. Inflammation has also been recognized to involve in PD [25–27]. Sustained inflammatory process and the activated microglia might drive the progressive degeneration of dopamine neurons in PD [28]. Moreover, the cytoplasmic HMGB1 has been indicated to control the cellular autophagy/apoptosis checkpoint during inflammation [29]. HMGB1 was demonstrated to mediate the persistent neuroinflammation and consequent progressive neurodegeneration, via stimulating the production of multiple inflammatory and neurotoxic factors [30]. In addition, HMGB1 has been recently indicated to involve in the autophagy inhibition caused by α-synuclein overexpression [31], implying a direct role in modulating autophagic degradation of α-synuclein.

In current study, we investigated the regulation of α-synuclein overexpression on the trans-location or the expression of HMGB1 and Beclin1, and on the starvation-induced autophagy in pheochromocytoma PC12 cells. And then we explored the overexpression of HMGB1 or Beclin1 on the α-synuclein degradation and on the autophagy in the α-synuclein-overexpressed PC12 cells. This study confirmed the positive regulation by endogenous HMGB1 on the autophagy-mediated α-synuclein degradation in PC12 cells.

Methods

Construction of PC12 (Synwt) and PC12 (Synmt) cells

Rattus norvegicus pheochromocytoma PC12 cell line was purchased from American Type Culture Collection (ATCC) (Rockville, MD, USA) and was cultured in RPMI-1640 medium (GIBCO, Rockville, MD, USA) supplemented with 10 % (2 % for maintaining) fetal bovine serum (FBS) (Hyclone, Pittsburgh, PA, USA) and with 100 U/mL penicillin and 100 mg/mL streptomycin (CSPC Pharmaceutical Group Limited, China). Cells were cultured at 37 °C in a humidified incubator with 5 % CO2. To construct an α-synuclein-overexpressed PC12 cell line, the wild-type (wt) (NM_019169.2), mutant-type (mt, A53T and A30P) α-synuclein coding sequence, or the Enhanced Green Fluorescence Protein (EGFP) coding sequence (as control) was amplified and cloned into the pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA, USA). Then we transfected the α-Syn(wt)-pcDNA3.1(+), α-Syn(mt)-pcDNA3.1(+) or EGFP-pcDNA3.1(+) plasmid into the 85 % confluent PC12 cells with lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After the transfection for 24 hours, cells were updated with the RPMI-1640 medium which were supplemented with 10 % FBS and with 1.2 mg/ml G418 (Life Technologies, Grand Island, NY, USA) to select the cell clone overexpressing wt or mt α-synuclein or EGFP. And the selected PC12 (Synwt), PC12 (Synmt) and PC12 (Con) cell clones were cultured in RPMI-1640 medium + 10 % FBS supplemented with 0.8 mg/ml G418. For the starvation treatment, PC12 (Synwt), PC12 (Synmt) and PC12 (Con) cells were inoculated with FBS-free RPMI-1640 medium at 37 °C in a humidified chamber with 5 % CO2.

Overexpression of HMGB1 or Beclin 1 in PC12 (Synwt) or PC12 (Synmt) cells

To promote the HMGB1 level in PC12 (Synwt) or PC12 (Synmt) cells, the coding sequence of HMGB1 or the coding sequence of Red Fluorescence Protein (RFP) was cloned into the pcDNA3.1(+) vector. And 5 μg/mL (to guarantee more than 90 % cells to be transfected) HMGB1-pcDNA3.1(+) or RFP-pcDNA3.1(+) plasmid was transfected into 105 per well 85 % confluent PC12 (Synwt) or PC12 (Synmt) cells. To upregulate the Beclin1 level in PC12 cells, Beclin1 or the coding sequence of Chloramphenicol acetyl transferase(CAT) was amplified and was cloned into the pLenti 6/TR vector (Invitrogen, Carlsbad, CA, USA). Recombinant pLenti-Beclin1 (LV-Beclin1) or pLenti-CAT virus of (LV-Con) was produced by cotransfecting 293 T cells with pLenti-Beclin1 or pLenti-CAT and ViraSafe™ Lentiviral Packaging System (Cell Biolabs, San Diego, CA, USA). PC12 (Synwt) or PC12 (Synmt) cells were infected with LV-Beclin1 or LV-Con virus with 1 Multiplicity of infection (MOI) for 12 or 24 hours.

mRNA isolation and real-time PCR analysis of α-synuclein mRNA

mRNA samples from OVCAR-3 cells were prepared with Kit for mRNA Isolation and Purification (Clontech, Palo Alto, CA, USA), and reverse transcription (RT) was performed with M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) as following: 42 °C for 5 min and 95 °C for 10 sec for the reverse transcription. And the real-time PCR assay was performed at 95 °C for 5 sec and 60 °C for 20 sec for the PCR reaction, with 40 cycles. The primer sequences for α-synuclein were as following: forward primer, 5’- CGT CCT CTA TGT AGG TTC CA -3’, reverse primer: 5’- GCC ACT GTT GTC ACT CCA TG -3’. The primer sequences for β-actin were as following: forward primer, 5’- GTA CCC TGG CAT TGC CGA CA -3’, reverse primer: 5’- GGA CTC GTC ATA CTC CTG CTT GCT -3’. Relative α-synuclein mRNA level was normalized to internal control β-actin, with the ∆∆Ct method [32].

Western blotting assay

PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells were homogenized with an ice-cold NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce, Rockford, IL, USA), the nuclear and the cytoplasmic proteins were isolated according to the product’s manual. Each protein sample was supplemented with a protease Inhibitor Cocktail (Abcam, Cambridge, UK) and was stored at -80 °C before use. The western blotting assay was performed with the rabbit polyclone antibody against α-synuclein (Abcam, Cambridge, UK), against HMGB1(Abcam, Cambridge, UK), against Beclin1 (Cell Signaling Technology Inc., Danvers, MA, USA), against LC3 (Pierce, Rockford, IL, USA), Atg 7 (Sigma-Aldrich, St. Louis, MO, USA), against mTOR (Abcam, Cambridge, UK), against LMNB1 (Pierce, Rockford, IL, USA) or against β-actin (Sinobio, Beijing, China), and with horseradish peroxidase-linked secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA). The specific binding band was scanned and quantified according to the band density.

Quantitative EGFP-LC3 analysis and electron microscopy

1 × 105 cells/well PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells were transfected with 2 μg EGFP-LC3 reporter plasmid, pcDNA3.1-EGFP-LC3, with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) for a 24 hour’s incubation to quantify the EGFP-positive autophagic vesicles which were promoted by various treatments. Then the EGFP-positive vesicles were visualized under fluorescence microscopy (JEM1230, Japan).

Statistical evaluations

Quantitative data was presented as mean ± SE and was analyzed for a significant difference with the Student’s t test or one way ANOVA test. A p value less than 0.05 was considered to be statistically significant.

Results

α-synuclein overexpression inhibits the trans-location of HMGB1 and the expression of Beclin1 in PC12 cells

To investigate the regulation of α-synuclein overexpression on the trans-location or the level of HMGB1 and Beclin1, and on the starvation-induced autophagy in pheochromocytoma PC12 cells, we constructed the PC12 cell overexpressing WT α-synuclein, PC12 (Synwt), or the PC12 cell overexpressing MT (A53T and A30P) α-synuclein, PC12 (Synmt), with PC12 (Con), which overexpressed enhanced green fluorescent protein (EGFP), as control. As shown in Fig. 1a, the mRNA level of α-synuclein was significantly higher in both PC12 (Synwt) and PC12 (Synmt) cells, compared with the PC12 (Con) or blank PC12 cells (either p < 0.001 for PC12 (Synwt) or PC12 (Synmt) cells). And the protein level of α-synuclein was confirmed by the western blot analysis in the PC12 (Synwt) or PC12 (Synmt) cells (p < 0.001 respectively, Fig. 1b). And then we investigated the influence of α-synuclein overexpression on the Beclin1 level and the trans-location of HMGB1 from nucleus to cytosol. Western blotting (Fig. 1c) demonstrated that the cytosolic HMGB1 was markedly upregulated, whereas was significantly downregulated in nucleus in either PC12 (Synwt) or PC12 (Synmt) cells (p < 0.05 respectively, Fig. 1c). In addition the cytoplasmic Beclin1 was also examined with western blot analysis. It was indicated that the Beclin level was significantly downregulated in both PC12 (Synwt) and PC12 (Synmt) cells (p < 0.01 respectively, Fig. 1d). Thus, we confirmed the promotion to the trans-location of HMGB1 from nucleus to cytosol, and to the cytoplasmic level of Beclin1 in PC12 cells.

Fig. 1
figure 1

Overexpression of α-synuclein with wild type (wt) or mutant type (mt) reduces cytosolic HMGB1 and Beclin1 in PC12 cells. a and b: mRNA (a) and protein (b) levels of α-synuclein in the PC12 cell overexpressing wt α-synuclein, PC12 (Synwt), in the PC12 cell overexpressing mt (A53T and A30P) α-synuclein, PC12 (Synmt), in the PC12 cell overexpressing Enhanced Green Fluorescence Protein (EGFP), PC12 (Con), or in the blank P12 cells, the protein level of α-synuclein was examined by western blot analysis; c: Western blot analysis of HMGB1 (in cytosol and in nucleus) and Beclin1 (in cytosol) in PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells; d: Relative HMGB1 level to β-actin in cytosol or to Lamin B(LMNB1) in the nucleus of PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells; e: Relative Beclin1 level to β-actin in the cytosol of PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells; Each result was averaged for triple independent experiments. Statistical significance was presented as * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance

Full size image

α-synuclein overexpression inhibits autophagy in PC12 cells

We then examined the regulation of the overexpressed α-synuclein on the autophagy in PC12 cells. The autophagy induction in PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells subject to starvation was examined with western blotting assay and the EGFP-LC3 reporter assay. Western blotting results (Fig. 2a) demonstrated that the conversion of LC3-I to LC3-II was markedly lower in either PC12 (Synwt) or PC12 (Synmt) cells, compared to the normal PC12 or the PC12 (Con) cells (p < 0.01 respectively, Fig. 2b). And such reduced autophagy was also confirmed by the reduced level of Atg7 and increased level of mTOR in either PC12 (Synwt) or PC12 (Synmt) cells (p < 0.01 respectively, Fig. 2b). Moreover, the EGFP-LC3 reporter assay also demonstrated that there were less GFP-positive autophagic puncta in either PC12 cells. Taken together, the α-synuclein overexpression with wild or mutant type inhibits the starvation-stimulated autophagy in PC12 cells.

Fig. 2
figure 2

Levels of autophagy-associated markers and autophagic vesicles induced by starvation in the PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells. a: Western blotting assay of LC3-I, LC3-II, Atg 7 and mTOR in the PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells post an incubation at 37 °C in FBS-free medium for 24 hours; b: Ratio of LC3-II to LC3-I in the starvation-treated cell lines; c: Relative level of Atg 7 and mTOR levels to β-actin in each cell line post the starvation treatment; d and e: Imaging (d) and counting (e) of EGFP-positive autophagic vesicles in the cytosol of starvation-treated PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells which were transfected with pCDNA3.1-EGFP-LC3 plasmid for another 24 hours; Data was averaged for triple independent results. * p < 0.05, ** p < 0.01, ns: no significance

Full size image

HMGB1 promotes autophagy and α-synuclein degradation in the α-synuclein-overexpressed PC12 cells

To investigate the role of HMGB1 on the autophagic degradation of α-synuclein, we overepressed HMGB1 in both PC12 (Synwt) and PC12 (Synmt) cells with the gain-of-function strategy, and then re-evaluated the starvation-induced autophagy in both cell lines. Western blotting assay (Fig. 3a) demonstrated that the transfection with HMGB1-pcDNA3.1(+) (pc-HMGB1) dramatically upregulated the HMGB1 level in both PC12 (Synwt) (Fig. 3b) and PC12 (Synmt) (Fig. 3c) cells at 12 or 24 hour post transfection (H.P.T.) (p < 0.01 or p < 0.001), and time-dependently (p < 0.05). However, the α-Synuclain level was markedly downregulated in both PC12 (Synwt) (Fig. 3d) and PC12 (Synmt) (Fig. 3e) cells (p < 0.05 respectively). Moreover, the EGFP-LC3 reporter assay (Fig. 3f) demonstrated that the overexpressed HMGB1 promoted more autophagic vesicles in either PC12 (Synwt) or PC12 (Synmt) cells which were subject to starvation. Therefore, HMGB1 promotes α-synuclein degradation and ameliorates the α-synuclein-mediated autophagy reduction in PC12 cells.

Fig. 3
figure 3

HMGB1 upregulation inhibits α-synuclein accumulation and ameliorates the α-synuclein-inhibited autophagy in PC12 (Synwt) and PC12 (Synmt) cells. a: Western blot analysis of HMGB1 and α-synuclein in PC12 (Synwt) and PC12 (Synmt) cells, which were transfected with HMGB1-pcDNA3.1(+) or RFP-pcDNA3.1(+) plasmid for 12 or 24 hours; b and c: Ratio of HMGB1 to β-actin in PC12 (Synwt) and PC12 (Synmt) cells with or without HMGB1 promoted; d and e: Ratio of α-synuclein to β-actin in PC12 (Synwt) and PC12 (Synmt) cells, with or without HMGB1 promoted; f and g: Imaging (f) and counting (g) of EGFP-positive autophagic vesicles in the cytosol of starvation-treated PC12 (Synwt) or PC12 (Synmt), with or without HMGB1 promoted. Each result was averaged for triple independent experiments. Statistical significance was presented as * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance

Full size image

In addition, we also investigated the influence of exogenous HMGB1 treatment on the starvation-induced autophagy in PC12 cells. Western blotting assay (Fig. 4a) demonstrated that the treatment with 0.2 to 1 μg/mL HMGB1 did not significantly regulate the conversion of LC3-I to LC3-II (Fig. 4b) and the expression of Atg 7 (Fig. 4c) and mTOR (Fig. 4d). Therefore, the exogenous HMGB1 exerts no regulation on the starvation-induced autophagy in PC12 cells.

Fig. 4
figure 4

Western blot analysis of autophagy-associated markers in the PC12 (Synwt) or the PC12 (Synmt) cells, which were treated with HMGB1. a: Western blotting assay of LC3-I, LC3-II, Atg 7 and mTOR in the PC12 (Synwt) cells which were treated with 0, 0.2, 0.5 or 1 μg/mL HMGB1, under starvation for 24 hours; b: Ratio of LC3-II to LC3-I in the starvation-treated PC12 (Synwt) cells with HMGB1 treatment; c and d: Relative level of Atg 7 (c) and mTOR (d) levels to β-actin in the PC12 (Synwt) cells with HMGB1 treatment; e: Western blotting assay of LC3-I, LC3-II, Atg 7 and mTOR in the PC12 (Synmt) cells which were treated with 0, 0.2, 0.5 or 1 μg/mL HMGB1, under starvation for 24 hours; f: Ratio of LC3-II to LC3-I in the starvation-treated PC12 (Synmt) cells with HMGB1 treatment; g and h: Relative level of Atg 7 (g) and mTOR (h) levels to β-actin in the PC12 (Synmt) cells with HMGB1 treatment. Data was averaged for triple independent results, ns: no significance

Full size image

Beclin1 overexpression promotes autophagy and α-synuclein degradation in the α-synuclein-overexpressed PC12 cells

Given the high importance of Beclin1-dependent autophagy in the α-synuclein degradation [10, 12], we then investigated the influence of Beclin1 overexpression on the α-synuclein degradation and the starvation-induced autophagy in both PC12 (Synwt) and PC12 (Synmt) cells. As shown in Fig. 5a, the lentivirus-mediated Beclin1 overexpression in protein level was significant in both cell lines (Fig. 5b and c) at either 12 or 24 H.P.I. (p < 0.001 respectively) with 1 multiplicity of infection (MOI) with the Beclin1-lentivirus (LV-Beclin1). And the α-synuclein level was markedly reduced at 12 or 24 H.P.I. in the LV-Beclin1-infected PC12 (Synwt) (either p < 0.05 for 12 or 24 H.P.I., Fig. 5d) or PC12 (Synmt) cells (p < 0.01 or p < 0.001 for 12 or 24 H.P.I., Fig. 5e). In addition, we examined the starvation-induced autophagic vesicles in each cell line with the EGFP-LC3 reporter assay. It was indicated in Fig. 5f and g that the infection with 1 MOI LV-Beclin1 promoted more autophagic vesicles than the LV-Con infection in either PC12 (Synwt) or PC12 (Synmt) cells (p < 0.05). Thus, we also confirmed the positive regulation by Beclin1 on the starvation-induced autophagy in PC12 cells.

Fig. 5
figure 5

Beclin1 upregulation reduces α-synuclein accumulation and ameliorates the α-synuclein-inhibited autophagy in PC12 (Synwt) and PC12 (Synmt) cells. a: Western blot analysis of Beclin1 and α-synuclein in the PC12 (Synwt) and PC12 (Synmt) cells which were infected with 1 multiplicity of infection (MOI) pLenti-Beclin1 (LV-Beclin1) or pLenti-Con (LV-Con) under starvation for 12 or 24 hours; b and c: Ratio of Beclin1 to β-actin in PC12 (Synwt) (b) and PC12 (Synmt) (c) cells which were infected with LV-Beclin1 or with LV-Con virus; d and e: Ratio of α-synuclein to β-actin in PC12 (Synwt) (b) and PC12 (Synmt) (c) cells which were infected with LV-Beclin1 or with LV-Con virus; f and g: Imaging (f) and counting (g) of EGFP-positive autophagic vesicles in the starvation-treated PC12 (Synwt) or PC12 (Synmt), which were infected with LV-Beclin1 or with LV-Con virus. Each result was averaged for triple independent experiments. Statistical significance was presented as * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance

Full size image

Discussion

HMGB1, as a cytokine-like factor [33], is increasingly recognized as a novel autophagy regulator via interfering with the PIK3C3 complex [34]. Nucleus-to-cytosol translocated HMGB1 competitively binds to Beclin1 and subsequently induces autophagy [35]. However, α-synuclein has been shown to impair the autophagy [36, 37]. In particular, α-synuclein could bind to both cytoplasmic and nuclear HMGB1, block HMGB1-Beclin1 binding, whereas to strengthen the Beclin1-BcL2 binding [31], and thus to inhibit autophagy. And such inhibition could be restored by the Beclin 1 overexpression. In the present study, we found that the overexpression of either WT or MT α-synuclein markedly reduced the cytoplasmic levels of both HMGB1 and Beclin1 in PC12 cells, implying the reduced HMGB1 and Beclin1 might contribute to the α-synuclein-mediated autophagy inhibition in PC12 cells.

Impaired autophagy has been indicated to correlate with the α-synuclein aggregation and neurodegeneration in PD [38–41]; and the stimulated autophagy could reduce the accumulation of α-synuclein in cells and in mouse brain [12, 42], and could even rescue midbrain dopamine neurons from α-synuclein toxicity [43]. On the other side, α-synuclein has been shown to impair autophagy [36, 37]. The overexpression of either WT or MT α-synuclein inhibits autophagy in pheochromocytoma PC12 cells [31], impairs neurite outgrowth of primary midbrain neurons, affects neurite branching [44]. In this study, we reconfirmed such autophagy inhibition by α-synuclein overexpression in PC12 cells, the overexpression of wild-type or mutant-type α-synuclein significantly downregulated the starvation-induced autophagy via inhibiting the mTOR/Atg 7 signaling. Therefore, we also confirmed the autophagy inhibition by the overexpressed α-synuclein in PC12 cells. And it implies that the reduced HMGB1 and Beclin1 might contribute to the reduced autopahgy in the α-synuclein-overexpressed PC12 cells.

HMGB1 is also known as the high-mobility group protein 1 (HMG-1). As a chromatin-associated nuclear protein, it is a critical regulator of autophagy. And the pharmacological inhibition of HMGB1 cytoplasmic translocation limits starvation-induced autophagy. Moreover, only endogenous HMGB1 has been indicated to regulate the Bcl-2-Beclin1 binding, via the direct interact with Beclin 1 [34, 35], and thus regulating the convergence of autophagy and apoptosis, via interacting with anti-apoptotic Bcl-2-like proteins [45]. Our study confirmed that either endogenous HMGB1 or Beclin 1 overexpression promoted the α-synuclein degradation in PC12 cells. Moreover, the overexpressed HMGB1 or Beclin 1 markedly ameliorated the α-synuclein-mediated autophagy reduction in the α-synuclein-overexpressed (either WT or MT) PC12 cells, implying the promotion by HMGB1 to the α-synuclein degradation might be autophagy-dependent. And such amelioration might be dependent on the HMGB1-Beclin1 interaction.

Interesting, our results indicated that the extracellular HMGB1 exerted no regulatory role on the starvation-induced autophagy, posing no influence on the levels of mTOR and Atg 7 in both PC12 (Synwt) and PC12 (Synmt) cells. HMGB1 is a secretary cytokine from activated macrophages and monocytes [46] to mediate inflammation [33], via binding to receptor for advanced glycation endproducts (RAGE) [47] or to toll-like receptor (TLR) [48]. However, the present study confirmed that the promotion by HMGB1 was not RAGE- or TLR-dependent. In addition, the gain-of-function strategy also confirmed the promotion to the α-synuclein degradation and the autophagy induction by Beclin1 overexpression in PC12 cells. Taken together, we speculated that endogenous HMGB1 and Beclin1 might promote the autophagic degradation of α-synuclein. Therefore, the endogenous HMGB1 and Beclin1 exerts protective role in the cells against the α-synuclein accumulation.

Conclusion

In summary, α-synuclein with wild-type or mutant-type inhibited autophagy in PC12 cells via inhibiting the HMGB1 and Beclin1. On the other side, the cytosolic promotion to HMGB1 or to Beclin1 up-regulates the autophagic degradation of α-synuclein via increasing the autophagy in PC12 cells. Therefore, the endogenous HMGB1 and Beclin1 present protective role in the cells against the α-synuclein accumulation.

Abbreviations

PD:

Parkinson disease

HMGB1:

High mobility group box 1

ALP:

Autophagy lysosomal pathway

WT:

Wild-type

(MT:

A53T and A30P), Mutant-type

ULK1:

Unc-51 like autophagy activating kinase 1

mTOR:

Mammalian target of rapamycin

PIK3C3:

Beclin 1-Phosphatidylinositol 3-kinase catalytic subunit type 3

ATG:

Autophagy-related protein

VPS34:

Vacuolar protein sorting 34

ROCK1:

Rho-associated, coiled-coil containing protein kinase 1

Mst1:

Macrophage stimulating 1

PC12 (Synmt):

PC12 cell overexpressing MT (A53T and A30P) α-synuclein

PC12 (Synwt):

PC12 cell overexpressing WT α-synuclein

References

  1. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998;57(4):334–7.

    Article  PubMed  CAS  Google Scholar 

  2. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469–73.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Ebrahimi-Fakhari D, McLean PJ, Unni VK. Alpha-synuclein’s degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy. 2012;8(2):281–3.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson’s disease: curse or blessing. Acta Neuropathol. 2012;124(2):153–72.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Shacka JJ, Roth KA, Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci. 2008;13:718–36.

    Article  PubMed  CAS  Google Scholar 

  6. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain. 2008;131(Pt 8):1969–78.

    Article  PubMed  Google Scholar 

  7. Ding WX, Yin XM. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy. 2008;4(2):141–50.

    Article  PubMed  CAS  Google Scholar 

  8. Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(5):a9423.

    Article  Google Scholar 

  9. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90(4):1383–435.

    Article  PubMed  CAS  Google Scholar 

  10. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci. 2009;29(43):13578–88.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Wong PM, Feng Y, Wang J, Shi R, Jiang X. Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A. Nat Commun. 2015;6:8048.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Chen LL, Song JX, Lu JH, Yuan ZW, Liu LF, Durairajan SS, et al. Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway. J Neuroimmune Pharmacol. 2014;9(3):380–7.

    Article  PubMed  Google Scholar 

  13. Moreau K, Ghislat G, Hochfeld W, Renna M, Zavodszky E, Runwal G, et al. Transcriptional regulation of Annexin A2 promotes starvation-induced autophagy. Nat Commun. 2015;6:8045.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Ma B, Cao W, Li W, Gao C, Qi Z, Zhao Y, et al. Dapper1 promotes autophagy by enhancing the Beclin1-Vps34-Atg14L complex formation. Cell Res. 2014;24(8):912–24.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Zhao J, Wang ML, Li Z, Gao DM, Cai Y, Chang J, et al. Interferon-alpha-2b induces autophagy in hepatocellular carcinoma cells through Beclin1 pathway. Cancer Biol Med. 2014;11(1):64–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  16. Gurkar AU, Chu K, Raj L, Bouley R, Lee SH, Kim YB, et al. Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. Nat Commun. 2013;4:2189.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Maejima Y, Kyoi S, Zhai P, Liu T, Li H, Ivessa A, et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med. 2013;19(11):1478–88.

    Article  PubMed  CAS  Google Scholar 

  18. Pan CC, Kumar S, Shah N, Bloodworth JC, Hawinkels LJ, Mythreye K, et al. Endoglin Regulation of Smad2 Function Mediates Beclin1 Expression and Endothelial Autophagy. J Biol Chem. 2015;290(24):14884–92.

    Article  PubMed  CAS  Google Scholar 

  19. Sun X, Tang D. HMGB1-dependent and -independent autophagy. Autophagy. 2014;10(10):1873–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al. HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 2012;72(1):230–8.

    Article  PubMed  CAS  Google Scholar 

  21. Luo Y, Yoneda J, Ohmori H, Sasaki T, Shimbo K, Eto S, et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res. 2014;74(1):330–40.

    Article  PubMed  CAS  Google Scholar 

  22. Perez-Carrion MD, Cena V. Knocking down HMGB1 using dendrimer-delivered siRNA unveils its key role in NMDA-induced autophagy in rat cortical neurons. Pharm Res. 2013;30(10):2584–95.

    Article  PubMed  CAS  Google Scholar 

  23. Hagiwara S, Iwasaka H, Hasegawa A, Kudo K, Kusaka J, Oyama Y, et al. Infusion of a glucose solution reduces autophagy in the liver after LPS-induced systemic inflammation. Inflammation. 2012;35(1):249–58.

    Article  PubMed  CAS  Google Scholar 

  24. Fang H, Liu A, Dahmen U, Dirsch O. Dual role of chloroquine in liver ischemia reperfusion injury: reduction of liver damage in early phase, but aggravation in late phase. Cell Death Dis. 2013;4:e694.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Monahan AJ, Warren M, Carvey PM. Neuroinflammation and peripheral immune infiltration in Parkinson’s disease: an autoimmune hypothesis. Cell Transplant. 2008;17(4):363–72.

    PubMed  Google Scholar 

  26. Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–97.

    Article  PubMed  CAS  Google Scholar 

  27. Przedborski S. Inflammation and Parkinson’s disease pathogenesis. Mov Disord. 2010;25 Suppl 1:S55–7.

    Article  PubMed  Google Scholar 

  28. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 2007;35(Pt 5):1127–32.

    Article  PubMed  CAS  Google Scholar 

  29. Zhu X, Messer JS, Wang Y, Lin F, Cham CM, Chang J, et al. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J Clin Invest. 2015;125(3):1098–110.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 2011;31(3):1081–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z, et al. HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy. 2014;10(1):144–54.

    Article  PubMed  CAS  Google Scholar 

  32. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.

    Article  PubMed  CAS  Google Scholar 

  33. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248–51.

    Article  PubMed  CAS  Google Scholar 

  34. Kang R, Livesey KM, Zeh HJ, Loze MT, Tang D. HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy. 2010;6(8):1209–11.

    Article  PubMed  CAS  Google Scholar 

  35. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190(5):881–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Winslow AR, Rubinsztein DC. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy. 2011;7(4):429–31.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Ferrucci M, Pasquali L, Ruggieri S, Paparelli A, Fornai F. Alpha-synuclein and autophagy as common steps in neurodegeneration. Parkinsonism Relat Disord. 2008;14 Suppl 2:S180–4.

    Article  PubMed  Google Scholar 

  38. Plotegher N, Civiero L. Neuronal autophagy, alpha-synuclein clearance, and LRRK2 regulation: a lost equilibrium in parkinsonian brain. J Neurosci. 2012;32(43):14851–3.

    Article  PubMed  CAS  Google Scholar 

  39. Friedman LG, Lachenmayer ML, Wang J, He L, Poulose SM, Komatsu M, et al. Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain. J Neurosci. 2012;32(22):7585–93.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  40. Malkus KA, Ischiropoulos H. Regional deficiencies in chaperone-mediated autophagy underlie alpha-synuclein aggregation and neurodegeneration. Neurobiol Dis. 2012;46(3):732–44.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Li G, Yang H, Zhu D, Huang H, Liu G, Lun P. Targeted suppression of chaperone-mediated autophagy by miR-320a promotes alpha-synuclein aggregation. Int J Mol Sci. 2014;15(9):15845–57.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, et al. Latrepirdine stimulates autophagy and reduces accumulation of alpha-synuclein in cells and in mouse brain. Mol Psychiatry. 2013;18(8):882–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  43. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci U S A. 2013;110(19):E1817–26.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  44. Koch JC, Bitow F, Haack J, D’Hedouville Z, Zhang JN, Tonges L, et al. Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death Dis. 2015;6:e1811.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  45. Liang XH, Kleeman LK, Jiang HH, Gordon G, Goldman JE, Berry G, et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol. 1998;72(11):8586–96.

    PubMed  CAS  PubMed Central  Google Scholar 

  46. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med. 2008;14(7-8):476–84.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  47. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–88.

    Article  PubMed  CAS  Google Scholar 

  48. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26(2):174–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The present study was supported by the grant from the Science and Technology Project from Guangxi Science and Technology Bureau (GKG1355005-4-3).

Author information

Author notes

    Authors and Affiliations

    1. Department of Neurology, RuiKang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, 530011, China

      Kaihua Wang, Jianmin Huang, Longjian Huang & Canhua Zhong

    2. Southern Medical University, Guangzhou, Guangdong, 510515, China

      Wei Xie

    3. Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China

      Wei Xie

    4. School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China

      Wei Xie

    5. Guangxi University of Chinese Medicine, Nanning, Guangxi, 530001, China

      Zhenzhen Chen

    Authors
    1. Kaihua Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jianmin Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Wei Xie
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Longjian Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Canhua Zhong
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Zhenzhen Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Wei Xie.

    Additional information

    Competing interests

    Authors declare no conflict of interests regarding the publication of this article.

    Authors’ contributions

    KHW, JMH and WX designed the research, KHW, JMH, LJH, CHZ and ZZC performed the experiments. KHW, JMH and WX conceived of the study, drafted the manuscript. KHW and ZZC performed the statistical analysis. All authors read and approved the final manuscript.

    Kaihua Wang and Jianmin Huang contributed equally to this work.

    Rights and permissions

    Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Reprints and Permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wang, K., Huang, J., Xie, W. et al. Beclin1 and HMGB1 ameliorate the α-synuclein-mediated autophagy inhibition in PC12 cells. Diagn Pathol 11, 15 (2016). https://doi.org/10.1186/s13000-016-0459-5

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/s13000-016-0459-5

    Keywords

    • Beclin1
    • HMGB1
    • α-synuclein
    • Autophagy
    • Pheochromocytoma PC12 cells

    Diagnostic Pathology

    ISSN: 1746-1596

    Contact us